A dual GLP-1R and CCK2 receptor agonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

ZP3022

Item No. 42636

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-histidylglycyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-leucyl-L-seryl-L-lysyl-L-glutaminyl-L-methionyl-L-α-glutamyl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-valyl-L-arginyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-α-glutamyl-L-tryptophyl-L-leucyl-L-lysyl-L-asparaginyl-2- [2-(2-aminoethoxy)ethoxy] acetyl-2-[2- (2-aminoethoxy)ethoxy] acetyl-L-tyrosylglycyl-L-tryptophyl-L-leucyl-L-α-aspartyl-L-phenylalaninamide
CAS Number
1345835-12-2
Molecular Formula
C199H294N48O61S
Formula Weight
4366.9
Purity
≥95%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Soluble: ≥10 mg/mlPBS (pH 7.2): Slightly soluble: 0.1-1 mg/ml
SMILES
O=C(COCCOCCNC(COCCOCCNC([C@H](CC(N)=O)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@H](CC1=CNC2=C1C=CC=C2)NC([C@H](CCC(O)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC3=CC=CC=C3)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@H](C(C)C)NC([C@H](C)NC([C@H](CCC(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CCSC)NC([C@H](CCC(N)=O)NC([C@H](CCCCN)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@H]([C@H](O)C)NC([C@H](CC4=CC=CC=C4)NC([C@H]([C@H](O)C)NC(CNC([C@H](CCC(O)=O)NC(CNC([C@H](CC5=CNC=N5)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CC6=CC=CC=C6)=O)CC(O)=O)=O)CC(C)C)=O)CC7=CNC8=C7C=CC=C8)=O)=O)CC9=CC=C(C=C9)O
InChi Code
InChI=1S/C199H294N48O61S/c1-17-108(12)165(196(302)230-133(58-64-161(268)269)181(287)237-144(87-117-93-213-124-45-30-28-43-121(117)124)188(294)234-136(78-103(2)3)183(289)222-126(47-32-34-67-201)176(282)238-145(89-151(204)254)172(278)210-70-72-306-73-75-307-100-155(258)209-69-71-305-74-76-308-101-156(259)221-140(85-115-49-51-119(252)52-50-115)173(279)216-96-153(256)220-143(86-116-92-212-123-44-29-27-42-120(116)123)187(293)233-138(80-105(6)7)185(291)239-146(90-162(270)271)189(295)231-135(168(205)274)82-112-36-21-18-22-37-112)246-191(297)141(83-113-38-23-19-24-39-113)236-184(290)137(79-104(4)5)232-177(283)127(48-35-68-211-199(206)207)229-195(301)164(107(10)11)245-169(275)109(13)218-174(280)130(55-61-158(262)263)225-179(285)131(56-62-159(264)265)226-180(286)132(57-63-160(266)267)227-182(288)134(65-77-309-16)228-178(284)129(53-59-150(203)253)224-175(281)125(46-31-33-66-200)223-193(299)148(98-248)242-186(292)139(81-106(8)9)235-190(296)147(91-163(272)273)240-194(300)149(99-249)243-198(304)167(111(15)251)247-192(298)142(84-114-40-25-20-26-41-114)241-197(303)166(110(14)250)244-154(257)97-215-171(277)128(54-60-157(260)261)219-152(255)95-214-170(276)122(202)88-118-94-208-102-217-118/h18-30,36-45,49-52,92-94,102-111,122,125-149,164-167,212-213,248-252H,17,31-35,46-48,53-91,95-101,200-202H2,1-16H3,(H2,203,253)(H2,204,254)(H2,205,274)(H,208,217)(H,209,258)(H,210,278)(H,214,276)(H,215,277)(H,216,279)(H,218,280)(H,219,255)(H,220,256)(H,221,259)(H,222,289)(H,223,299)(H,224,281)(H,225,285)(H,226,286)(H,227,288)(H,228,284)(H,229,301)(H,230,302)(H,231,295)(H,232,283)(H,233,293)(H,234,294)(H,235,296)(H,236,290)(H,237,287)(H,238,282)(H,239,291)(H,240,300)(H,241,303)(H,242,292)(H,243,304)(H,244,257)(H,245,275)(H,246,297)(H,247,298)(H,260,261)(H,262,263)(H,264,265)(H,266,267)(H,268,269)(H,270,271)(H,272,273)(H4,206,207,211)/t108-,109-,110+,111+,122-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,164-,165-,166-,167
InChi Key
NNIQIOUWVDDUSE-GGXPHKMXSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $60

    Add

    5 mg

    $268

    Add

    10 mg

    $476

    Add

    25 mg

    $1,040

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    ZP3022 is a dual agonist of the glucagon-like peptide 1 receptor (GLP-1R) and cholecystokinin 2 (CCK2) receptor.1 It selectively increases cAMP accumulation or ERK phosphorylation in HEK293 cells expressing GLP-1R or the CCK2 receptor over ERK phosphorylation in HEK293 cells expressing the CCK1 receptor (EC50s = 0.02, 10.3, and >1,000 nM, respectively, for the human receptors). ZP3022 (40 nM) increases the proliferation of rat neonatal β-cells in vitro.2 It also increases glucose-induced insulin secretion (GSIS) in rat pancreatic islets when used at concentrations of 10 and 100 nM and reduces body weight in rats when administered at a dose of 40 nmol/kg twice per day. ZP3022 (100 nmol/kg per day) increases β-cell mass and total pancreatic mass and improves glucose tolerance in db/db mice.1 It also reduces food intake but not body weight in db/db mice.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Fosgerau, K., Jessen, L., Lind Tolborg, J., et al. The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice. Diabetes Obes. Metab. 15(1), 62-71 (2013).

    2. Skarbaliene, J., Rigbolt, K.T., Fosgerau, K., et al. In-vitro and in-vivo studies supporting the therapeutic potential of ZP3022 in diabetes. Eur. J. Pharmacol. 815, 181-189 (2017).